
Amgen appoints Mattel’s Robert Eckert to Board of directors
pharmafile | December 14, 2012 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Amgen, Eckert
Biotech firm Amgen has announced the appointment of Robert Eckert, former chief executive officer at Mattel, to its Board of directors.
Eckert will serve on the Audit and Corporate Responsibility and Compliance Committees for the firm. Following the appointment of Eckert and previously announced retirement of Kevin Sharer, the Board from the new year will be comprised of 14 directors, 13 of whom are independent.
“We are pleased to welcome Bob Eckert to the Amgen Board. Bob has significant experience and a superb track record of leading global companies during a long and successful career,” said Robert Bradway, chief executive at Amgen who has himself just been appointed as chair of the Board of directors for the firm.
Related Content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer
Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) …

Amgen opens new biomanufacturing facility in Ohio, US
Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. …

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial
AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …






